MannKind Corporation (NASDAQ:MNKD) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET

Company Participants

Michael Castagna – Chief Executive Officer

Steven Binder – Chief Financial Officer

Conference Call Participants

Brandon Folkes – Cantor Fitzgerald

Gregory Renza – RBC Capital Markets

Thomas Smith – SVB Securities

Bert Hazlett – BTIG

Operator

Good afternoon and welcome to the MannKind Corporation First Quarter 2022 Earnings Call. As a reminder, this call is being recorded on May 5, 2022, and will be available for playback on the MannKind Corporation's website shortly after the conclusion of this call until May 19, 2022.

This call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the stated expectations.

For further information on the company's risk factors, please see their 10-K report filed with the Securities and Exchange Commission this afternoon, the earnings release, and the slides prepared for this presentation.

Joining us today from MannKind are Chief Executive Officer, Michael Castagna; and Chief Financial Officer, Steven Binder.

I would now like to turn the conference over to Mr. Castagna. Please go ahead sir.

Michael Castagna

Thank you. And thank you all for dialing into our earnings call today. We're in unprecedented times, as we look at the volatility in the stock market, as well as our biotech sector having lots of unfortunately mishaps these days in terms of companies employing on a daily basis, which from a MannKind perspective, we're expanding and hiring. So we're able to find great talent. But from an industry perspective, we see lots of change ahead.

When I think about Q1, we had some great opportunities to continue to advance our transformation in Afrezza, which I'll talk about today, as well as advance our pipeline progress with clofazimine and we'll give an update we know today on Tyvaso. So those will be the three focuses of our conversation.

I personally just got back from our ATTD Diabetes Conference in Europe, and I was able to meet about 10, 15 of the top regional thought leaders in those countries that are represented in the European Union to really talk about Afrezza, the potential of Afrezza, as well as the pediatric trial and the studies that we're doing. And I walked back, invigorated on opportunities on how we can continue to advance the science within diabetes.

We've also had several FDA interactions on Afrezza in the pipeline, trying to think about the label change, as well as preparing to go to advance clofazimine into Phase 2. And we also had Advisory Board with roughly 10 of the top thought leaders in nontuberculous mycobacteria, for the first time where we could really assess how we think about NTM, how we're positioning clofazimine, and to confirm our strategic direction relative to where we're going in our clinical trial, before we go to the FDA.